Related Experiment Videos

Nonketotic hyperglycinemia treated with strychnine, a glycine receptor antagonist

Helvetica Paediatrica Acta
|February 1, 1978
PubMed

Insights

Strychnine treatment improved motor skills and behavior in an infant with nonketotic hyperglycinemia. This suggests strychnine may counteract glycine

Area of Science:

  • Neuroscience
  • Pediatric Neurology
  • Pharmacology

Background:

  • Nonketotic hyperglycinemia (NKH) is a rare metabolic disorder characterized by excessive glycine levels.
  • Glycine acts as an inhibitory neurotransmitter in the central nervous system, particularly at spinal and brainstem levels.
  • Current treatments for NKH are limited, highlighting the need for novel therapeutic strategies.

Observation:

  • A 6.5-month-old infant diagnosed with nonketotic hyperglycinemia received oral strychnine therapy for over 12 months.
  • The patient exhibited notable improvements in muscle tone, motor function, alertness (vigilance), and social interactions during treatment.

Findings:

  • Strychnine, a known antagonist of glycine receptors, appeared to reverse the inhibitory effects of excessive glycine.
  • Improved motor function was likely due to strychnine blocking glycine-mediated inhibition of motor neurons.
  • Enhanced vigilance and social behavior may stem from strychnine's antagonism of glycine inhibition in brainstem reticular neurons.

Implications:

  • Strychnine shows potential as a therapeutic agent for nonketotic hyperglycinemia, addressing both motor and cognitive/behavioral symptoms.
  • This case suggests a potential role for glycine receptor antagonists in managing certain neurological disorders.
  • Further research is warranted to explore the efficacy and safety of strychnine in a larger cohort of NKH patients.

Related Concept Videos